1. Home
  2. MYSE vs INTS Comparison

MYSE vs INTS Comparison

Compare MYSE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myseum Inc.

MYSE

Myseum Inc.

N/A

Current Price

$1.37

Market Cap

14.2M

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

N/A

Current Price

$3.24

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYSE
INTS
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
13.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MYSE
INTS
Price
$1.37
$3.24
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $19.33
AVG Volume (30 Days)
★ 26.9K
18.4K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 56.64
N/A
EPS
★ N/A
N/A
Revenue
★ $550.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 26.15
N/A
52 Week Low
$1.37
$0.22
52 Week High
$11.54
$8.06

Technical Indicators

Market Signals
Indicator
MYSE
INTS
Relative Strength Index (RSI) 33.76 44.39
Support Level N/A $3.10
Resistance Level $3.61 $4.04
Average True Range (ATR) 0.10 0.24
MACD 0.03 0.03
Stochastic Oscillator 10.46 55.17

Price Performance

Historical Comparison
MYSE
INTS

About MYSE Myseum Inc.

Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: